Cost-effectiveness analysis of increased adalimumab dose intervals in Crohn's disease patients in stable remission: the randomised controlled LADI trial.
Fenna M JansenReinier Cornelis Anthonius van LinschotenWietske KievitLisa J T SmitsRenske W M PauwelsDirk J de JongAnnemarie C de VriesPaul J BoekemaRachel L WestAlexander G L BodelierIngrid A M GisbertzFrank H J WolfhagenTessa E H RömkensMaurice W M D LutgensAdriaan A van BodegravenBas OldenburgMarieke J PierikMaurice G V M RusselNanne K de BoerRosalie C Mallant-HentPieter C J Ter BorgAndrea E van der Meulen-de JongJeroen M JansenSita V JansenAdrianus C I T L TanFrank HoentjenC Janneke van der Woudenull nullPublished in: Journal of Crohn's & colitis (2023)
When the loss of a quality-adjusted life year is valued at less than €53,960, increasing the adalimumab dose interval is a cost-effective strategy in CD patients in stable clinical and biochemical remission.